Immunohistochemical Correlates of Response to Recombinant Interleukin-2-based Immunotherapy in Humans

Cancer Research

Volumn 49, Issue , 1989, Pages 7086-7092

  Rubin, Joshua T ^a   Elwood, Lori J ^a   Rosenberg, Steven A ^a   Lotze, Michael T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG COMBINATION; DRUG THERAPY; HISTOCHEMISTRY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; HLA-D ANTIGENS; HUMAN; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; KIDNEY NEOPLASMS; MACROPHAGES; MELANOMA; NEOPLASM METASTASIS; NEOPLASMS; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0024827393     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S.,Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. Seipp, C. A., Simpson, C., and Reichert, C. M. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med., 313: 1485-1492, 1985.
2. Rosenberg, S. A. The development of new immunotherapies for the treatment of cancer using interleukin-2. Ann. Surg., 208: 121-135, 1988.
3. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., and White, D. E. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med., 319: 1676-1680, 1988.
4. Cohen, P. J., Lotze, M. T., Roberts, J. R., Rosenberg, S. A., and JafTe, E. S. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2: correlation of response with T cell infiltration and HLA-DR expression. Am. J. Pathol., 129: 208-216, 1987.
5. DeLellis, R. A., Stemberger, L. A., Mann, R. B., Banks, P. M., and Nakane, P. K. Immunoperoxidase techniques in diagnostic pathology. Am. J. Clin. Pathol., 71:483-488, 1979.
6. Hsu, S-M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J. Histochem. Cytochem., 29: 577-580, 1981.
7. Mule, J. J., Yang, J. C., Lafreniere, R., Shu, S., and Rosenberg, S. A. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J. Immunol., 139: 285-294, 1987.
8. Peace, D. J., and Cheever, M. A. Toxicity and therapeutic efficacy of high-dose interleukin-2. J. Exp. Med., 169: 161-173, 1989.
9. Komstein, M. J., Brooks, J. S. J., and Elder, D. E. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res., 43: 2749-2753, 1983.
10. Shimokawara, I., Imamura, M., Yamanaka, N., Ishii, Y., and Kikuchi, K. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance. Cancer (Phila.), 49: 1456-1464, 1982.
11. Lucas-Martin, A., Foz-sala, M., Todd, I., Bottazzo, G. F., and Pujol-Borrell, R. Occurrence of thyrocyte HLA class II expression in a wide variety of thyroid diseases: relationship with lymphocyte infiltration and thyroid autoantibodies. J. Clin. Endocrinol. Metab., 66: 367-374, 1988.
12. Houghton, A. N., Thomson, T. M., Gross, D., Oettgen, H. F., and Old, L. J. Surface antigens of melanoma and melanocytes: specificity of induction of la antigens by human γ-interferon. J. Exp. Med., 160: 255-269, 1984.
13. Momburg, F., Degener, T., Bacchus, E., Moldenhauer, G., Hammerling, G. J., and Moller, P. Loss of HLA-A, B, C and de novo expression of HLA-D in colorectal cancer. Int. J. Cancer, 37: 179-184, 1986.
14. Thompson, J. J., Herlyn, M. F., Elder, D. E., Clark, W. H., Steplewski, Z., and Koprowski, H. Expression of DR antigens in freshly frozen human tumors. Hybridoma, 7:61-168, 1982.
15. Winchester, R. J., Wang, C-Y., Gibofsky, A., Kunkel, H. G., Lloyd, K. O., and Old, L. J. Expression of Ia-like antigens on cultured human malignant melanoma cell lines. Proc. Natl. Acad. Sci. USA, 75:6235-6239, 1978.
16. Fleming, K. A., McMichael, A., Morton, J. A., Woods, J., and McGee, J. Distribution of HLA class I antigens in normal human tissue and in mammary cancer. J. Clin. Pathol., 34: 779-784, 1981.
17. Natali, P. G., De Martino, C., Quaranta, V., Nicotra, M. R., Frezza, F., Pellegrino, M. A., and Ferrone, S. Expression of Ia-like antigens in normal human non-lymphoid tissues. Transplantation, 31: 75-78, 1981.
18. Koyama, K., Fukunishi, T., Barcos, M., Tanigaki, N., and Pressman, D. Human Ia-like antigens in non-lymphoid organs. Immunology, 38:333-341, 1979.
19. Bhan, A. K., and DesMarais, C. L. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. J. Natl. Cancer Inst., 72: 507-516, 1983.
20. Csiba, A., Whitwell, H. L., and Moore, M. Distribution of histocompatibility and leukocyte differentiation antigens in normal human colon and in benign and malignant neoplasms. Br. J. Cancer, 50:699-709, 1984.
21. Pober, J. S., and Gimbrone, M. A. Expression of Ia-like antigens by human vascular endothelial cells is inducible in vitro: demonstration by monoclonal antibody binding and immunoprecipitation. Proc. Natl. Acad. Sci. USA, 79: 6641-6645, 1982.
22. Cotran, R. S., Pober, J. S., Gimbrone, M. A., Springer, T. A., Wiebke, E. A., Gaspari, A. A., Rosenberg, S. A., and Lotze, M. T. Endothelial activation during interleukin-2 immunotherapy: a possible mechanism for the vascular leak syndrome. J. Immunol., 140: 1883-1888, 1988.
23. Ruiter, D. J., Bhan, A. K., Harrist, T. J., Sober, A. J., and Mihm, M. C. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J. Immunol., 729:2808-2815, 1982.
24. Brocker, E-B., Suter, L., Bruggen, J., Ruiter, D. J., Macher, E., and Sorg, C. Phenotypic dynamics of tumor progression in human malignant melanoma. Int. J. Cancer, 36: 29-35, 1985.
25. Weber, J. S., Jay, G., Tanaka, K., and Rosenberg, S. A. Immunotherapy of murine tumors with interleukin-2. J. Exp. Med., 166: 1716-1733, 1987.
26. Topalian, S. L., Solomon, D., and Rosenberg, S. A. Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol, in press, 1989.
27. Fossati, G., Taramelli, D., Balsari, A., Bogdanovich, G., Andreola, S., and Parmiani, G. Primary but not metastatic melanomas expressing DR antigens stimulate autologous lymphocytes. Int. J. Cancer, 33: 591-597, 1984.
28. Guerry, D., Alexander, M. A., Herlyn, M. F., Zehngebot, L. M., Mitchell, K. F. Zmijewski, C. M., and Lusk, E. J. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J. Clin. Invest., 73: 267-271, 1984.
29. Guerry, D., Alexander, M. A., Elder, D. E., and Herlyn, M. F. Interferon-7 regulates the T cell response to precursor nevi and biologically early melanoma. J. Immunol., 139: 305-312, 1987.
30. Brocker, E-B., Suter, L., and Sorg, C. HLA-DR antigen expression in primary melanomas of the skin. J. Invest. Dermatol., 82: 244-247, 1984.
31. Taramelli, D., Fossati, G., Mazzochi, A., Delia, D., Ferrone, S., and Parmi-ani, G. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res., 46:433-439, 1986.
32. Holzmann, B., Brocker, E. B., Lehmann, J. M., Ruiter, D. J., Sorg, C., Riethmuller, G., and Johnson, J. P. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int. J. Cancer, 39:466-471, 1987.
33. Natali, P. G., Cavaliere, R., Bigotti, A., Nicotra, M. R., Russo, C., Ng, A. K. Giacomini, P., and Ferrone, S. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J. Immunol., 130: 1462-1466, 1983.
34. Natali, P. G., Bigotti, A., Cavaliere, R., Ruiter, D. J., and Ferrone, S. HLA Class 11 antigens synthesized by melanoma cells. Cancer Rev., 9:1-33, 1988.
35. Ruiter, D. J., Bergman, W., Welvaart, K., Scheffer, E., Van Voloten, W. A., Russo, C., and Ferrone, S. lmmunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res., 44: 3930-3935, 1984.
36. Real, F. X., Houghton, A. N., Albino, A. O., Cordon-Cardo, Cl., Melamed, M. R., Oettgen, H. F., and Old, L. J. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies; specificity analysts and comparison of antigen expression in cultured cells and tissues. Cancer Res., 45:4401-4411, 1985.
37. Natali, P. G., Cordiali-Fei, P., Cavaliere, R., Di Fillippo, F., Quaranta, V., Pellegrino, M. A., and Ferrone, S. Ia-like antigens freshly explanted human melanoma. Clin. Immunol. Immunopathol., 19: 250-259 1981.
38. Albino, A. P., Lloyd, K. O., Houghton, A. N., Oettgen, H. F., and Old, L. J. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. J. Exp. Med., 154:1764-1778, 1981.
39. Scheurich, P., Kronke, M., Schluter, C., Ucer, U., and Pflzenmaier, K. Noncytocidal mechanisms of action of tumor necrosis factor-alpha on human tumor cells: enhancement of HLA gene expression synergistic with interferon-gamma. Immunobiol., 172: 291-300, 1986.
40. Rosa, F. M., and Fellous, M. Regulation of HLA gene by IFN-7: transcriptional and post-transcriptional control. J. Immunol., 140:1660-1664, 1988.
41. Basham, T. Y. and Merigan, T. C. Recombinant interferon-gamma increases HLA-DR synthesis and expression. J. Immunol., 130:1492-1494, 1983.
42. Schwartz, R., Momburg, F., Moldenhauer, G., Dorken, B., and Schirrmacher, V. Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-7. Int. J. Cancer, 35:245-250, 1985.
43. Wedgwood, J. F., Hatam, L and Bonagura, V. R. Effect of interferon-gamma and tumor necrosis factor on the expression of class I and class II major histocompatibility molecules by cultured human umbilical endothelial cells. Cell. Immunol., III: 1-9, 1988.
44. Pflzenmaier, K., Scheurich, P., Schluter, C., and Kronke, M. Tumor necrosis factor enhances HLA-A, B, C and HLA-DR gene expression in human tumor cells. J. Immunol., 138:975-980, 1987.
45. Todd, I., Pujol-Borrell, R., Hammond, L., Bottazzo, G. F., and Feldman, M. Interferon-7 induces HLA-DR expression by thyroid epithelium. Clin. Exp. Immunol., 61: 265-273, 1985.
46. Grabstein, K., Dower, S., Gillis, S., Urdal, D., and Larsen, A. Expression of interleukin-2, interferon-7, and the IL-2 receptor by human peripheral blood lymphocytes. J. Immunol., 136:4503-4508, 1986.
47. Reem, G. H., and Yeh, N-H. Interleukin-2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes. Science (Wash. DC),25:429-430, 1984.
48. Lotze, M. T., Malory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, C. A., Custer, M. C., and Rosenberg, S. A. In vivo administration of purified human interleukin-2: II. half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J. Immunol., 135: 2865-2875, 1985.
49. Rosenberg, S. A., Lotze, M. T., Aebersold, P. M., Yang, J. C., Chang, A. E., Avis, F. P., Boch, S. N., Schwartzentruber, D., Wei, J., Leitman, S., Linehan, W. M., Robertson, C. N., Seipp, C. A., Simpson, C. G., White, D. E., and Steinberg, S. M. Prospective randomized trial of high dose interleukin-2 alone or with lymphokine activated killer cells for the treatment of patients with advanced cancer. J. Clin. Oncol., in press, 1989.
50. Mitchell, M. S., Kempf, R. A., Harel, W., Shau, H., Boswell, W. D., Lind, S., and Bradley, E. C. Effectiveness and tolerability of low dose cyclophosphamide and low dose intravenous interleukin-2 disseminated melanoma. J. Clin. Oncol., 6:409-424, 1988.
51. Stotter, H., Wiebke, E. A., Tomita, S., Belldegrun, A., Topalian, S., Rosenberg, S. A., and Lotze, M. T. Cytokines alter target cell susceptibility to lysis: II. Evaluation of tumor infiltrating lymphocytes. J. Immunol., 142: 1767-1773, 1989.
52. Fisher, B., Packard, B. S., Read, E. J., Carrasquillo, J. A., Carter, C. S., Topalian, S. L., Yang, J. C., Yolles, P., Larson, S. M., and Rosenberg, S. A. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol., 7:250-261, 1989.